Because we are not aware of previous studies taking a similar approach for prostate cancer, we extensively compared our gene-level sCNA estimates to panel-based sequencing and Oncoscan data for a subset of BL patients, as well as to genetically validated and previously published PTEN and p53 IHC assays in the entire cohort (25, 29). This evidence concerns the gene TP53 and Burkitt lymphoma.